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Abstract
Background: Induced pluripotent stem cells (iPSCs) are a novel candidate for use in cardiac stem cell therapy. However,
their intrinsic tumorigenicity requires further investigation prior to use in a clinical setting. In this study we investigated
whether undifferentiated iPSCs are tumorigenic after intramyocardial transplantation into immunocompetent allogeneic
recipients.
Methodology/Principal Findings: We transplanted 2610
4,2 610
5,o r2 610
6 cells from the established rat iPSC line M13
intramyocardially into intact or infarcted hearts of immunocompetent allogeneic rats. Transplant duration was 2, 4, or 6
weeks. Histological examination with hematoxylin-eosin staining confirmed that undifferentiated rat iPSCs could generate
heterogeneous tumors in both intracardiac and extracardiac sites. Furthermore, tumor incidence was independent of cell
dose, transplant duration, and the presence or absence of myocardial infarction.
Conclusions/Significance: Our study demonstrates that allogeneic iPSC transplantation in the heart will likely result in in
situ tumorigenesis, and that cells leaked from the beating heart are a potential source of tumor spread, underscoring the
importance of evaluating the safety of future iPSC therapy for cardiac disease.
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Introduction
Induced pluripotent stem cells (iPSCs), first generated four years
ago from somatic cells via epigenetic reprogramming [1], offer
renewed hope for cardiac stem cell therapy. Previous studies have
shown that functional cardiomyocytes could be derived from
iPSCs in vitro [2,3]. Of note, one study reported that
intramyocardial delivery of undifferentiated mouse iPSCs within
infarcted mouse hearts achieved in situ regeneration of tumor-free
cardiac, smooth muscle and endothelial tissue in immunocompe-
tent recipients [4].
However, safety issues should be carefully evaluated prior to
clinical application. iPSCs are intrinsically tumorigenic [5]. It is
one of the criteria for pluripotency that iPSCs form teratoma in
immunocompromised recipients, typically after subcutaneous,
intramuscular or intratesticular transplantation. And there have
been studies reporting that undifferentiated or predifferentiated
iPSCs could also form teratomas in the heart [4] or nervous system
[6-8] of immunocompromised recipients. Whereas whether the
undifferenciated iPSCs will cause tumorigenesis in immunocom-
petent recipetent is still unknown, and no study has yet been
designed to evaluate the tumorigenicity of iPSCs in the cardiac
environment. Here, for the first time, we investigated the
tumorigenic potential of iPSCs after intramyocardial transplanta-
tion into immunocompetent allogeneic recipients and the possible
influence of cell dose, transplant duration, and the presence or
absence of myocardial infarction.
Results
We found that the M13 rat iPSC line maintained a stable
phenotype and karyotype throughout our experiments (Fig. 1).
Autopsy results revealed intracardiac and/or extracardiac
tumors in 19 out of 98 surviving Sprague-Dawley (SD) rats that
received iPSC transplants (details in Table 1). Typically, visible
intracardiac tumors extended from the left ventricular wall
(Fig. 2A, B), while extracardiac tumors spread in the left thoracic
cavity. No tumorigenesis was found in tissues collected from lung,
liver, spleen and kidney after histological examination. Intracar-
diac tumor incidence was significantly higher than that of
extracardiac tissues (P=0.001, Fig. 3E).
Hematoxylin-eosin-stained sections from harvested tumors
revealed cells that had differentiated to osteogenic (Fig. 2C, E),
cartilaginous (Fig. 2F, G), or neural lineages (Fig. 2H, I) among
the undifferentiated cells (Fig. 2C, D). Therefore, with no
endodermal differentiation observed, these tumors could not be
termed ‘‘teratomas’’ or ‘‘teratocarcinomas’’. Furthermore, the
incidence of mesodermal differentiation was significantly higher
than that of endodermal and ectodermal differentiation
(P,0.001, Fig. 3G).




6 iPSCs were delivered
intramyocardially into myocardial infarcted (MI) rats. However,
no significant difference in tumor incidence was found among
these conditions (Fig. 3A, B). This suggests that the tumorigenesis
observed in MI rats was dose independent within the numbers of
cells used for this experiment.
To evaluate the timecourse of tumorigenesis and differentiation,
we examined the engrafted cells 2, 4 or 6 weeks after
transplantation. We found no significant difference in tumor
incidence among time points (Fig. 3A, C). In addition, undiffer-
entiated cells were found at every time point examined.
To assess the possible influence of the host microenvironment
on in vivo differentiation of transplanted cells, we compared the
incidence of mesodermal and ectodermal differentiation between
intracardiac and extracardiac tumors, as well as MI versus intact
rats. Intracardiac tumors had a lower incidence of ectodermal
differentiation than extracardiac tumors (P=0.041), but no
significant difference in the incidence of mesodermal differentia-
tion was observed between intracardiac and extracardiac tumors
(Fig. 3H). In addition, there was no significant difference in
mesodermal or ectodermal differentiation between tumors gener-
ated in MI and intact myocardium (Fig. 3I). Furthermore, the
cardiac host microenvironment (MI versus intact myocardium)
had no significant effect on either total tumor incidence (Fig. 3D)
or intracardiac/extracardiac tumor incidence (Fig. 3F). Apart
from a slightly lower tendency toward ectodermal differentiation
in the myocardium compared to the thoracic cavity, these results
suggest that the host microenvironment had little influence on
tumor incidence and differentiation.
Discussion
In this report, we show that undifferentiated rat iPSCs can
generate heterogeneous tumors in intracardiac and extracardiac
sites after intramyocardial delivery in immunocompetent alloge-
neic rats. In addition, tumors formed in these rats regardless of cell
dose, transplant duration, or the presence or absence of MI.
In contrast to our results, previous work reported that intramyocar-
dial delivery of undifferentiated mouse iPSCs, generated by lentivirus-
mediated transduction with Oct4, Sox2, c-Myc and Klf4, resulted in
regeneration of cardiac, smooth muscle and endothelial tissue without
tumorigenesis in immunocompetent mice 8 weeks after transplantation
[4]. Also, embryonic stem cell (ESC) studies have suggested that the
cardiac microenvironment might provide paracrine signals to direct in
vivodifferentiation of ESCs intocardiomyocytes within 2 to 8 weeks [9-
11]. However, additional studies found no guided differentiation of
ESCs in the heart. Rather, teratoma formation was observed between
3 and 4 weeks after transplantation [12-14].
Figure 1. Verification of M13 rat iPSC characteristics. A, Mouse
embryonic stem cell-like colonies of M13 cells on a feeder layer. B,
Embryoid bodies on day 6 of a floating culture of M13 cells. C, Alkaline
phosphatase staining of M13 colonies. D, M13 cells maintain a normal
diploid karyotype of male rat origen (42XY) at passage 31. Scale bars:
100 mm.
doi:10.1371/journal.pone.0019012.g001
Table 1. Group Information and Tumor Formation.





sham no no 4 10 10 0
MI vehicle 0 4 10 6 0
MI MEFs 2610
4 41 05 0
MI riPSCs 2610
4 21 07 2
MI riPSCs 2610
4 41 08 1
MI riPSCs 2610
4 61 09 2
MI riPSCs 2610
5 21 08 1
MI riPSCs 2610
5 41 01 0 1
MI riPSCs 2610
5 61 07 1
MI riPSCs 2610
6 21 06 2
MI riPSCs 2610
6 43 02 4 5
MI riPSCs 2610
6 61 08 2
intact riPSCs 2610
6 41 11 1 2
MI = myocardial infarction; MEFs = irradiated mouse embryonic fibroblast cells; riPSCs = undifferentiated rat iPSCs.
doi:10.1371/journal.pone.0019012.t001
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guided differentiation in infarcted myocardium, which is likely to
release more paracrine factors, or intact myocardium, which is
considered as a less hostile microenvironment for stem cells to
survive. We observed that neither the infarcted nor intact cardiac
microenvironments could guide iPSCs toward the cardiac lineage.
Rather, heart tissue was permissive for the generation of tumors
consisting of undifferentiated as well as lineage-committed cells,
thus challenging the hypothesis of ‘‘host microenvironment guided
differentiation’’ of iPSCs.
We found no significant difference in tumor incidence among
the three doses of iPSCs tested. By contrast, some ESC
transplantation studies showed that tumor incidence was positively
correlated with the transplanted cell dose [13-15]. The results of
ESC studies may be explained that: 1) paracrine signals released
by the surrounding tissue might not permeate into the core of a
large cell graft, leaving cells to differentiate randomly; and 2)
autocrine factors released by pluripotent cells might accumulate
and trigger tumorigenesis in larger cell grafts. However, no
enhancement of cardiac differentiation has been discerned at the
margin versus the center of an intracardiac teratoma generated
from mESCs [13], in spite of an assumed better paracrine signal
permeation at the graft-host border. Moreover, teratomas have
been observed in transplants of as few as 2 ESCs [16], which is
presumably not a high enough cell number to accumulate
autocrine factors. Furthermore, the cell dose threshold for
tumorigenesis has been reported to range from 2 to hundreds of
thousands of ESCs [13-16], suggesting that experimental variation
is a major factor in tumorigenesis. Therefore, a safe cell dose
threshold may not be attainable presently for a given transplan-
tation setting, and more caution is appropriate.
The extracardiac tumors were found in the left thoracic cavities,
leaving organs with a typically high metastatic risk free of tumor.
Thus we postulate that these tumors originated from cells leaked
into the thoracic cavity during or after transplantation, rather than
from migrating cells. Hence, cell transplantation techniques should
be refined to improve cell retention, not only to enhance
transplant efficiency, but also to diminish the danger of tumor
spread.
No graft or tumor was evidenced in 80.6% of the surviving
recipients. There are 3 possible reasons. First, after injection into
beating myocardium, mechanical leakage and washout may
account for a major portion of cell loss after cell implantation
[17]. If these leaked cells retained in the thoracic cavities, they
could form extracardiac tumors as we observed in 3 cases. If the
cells completely washed out, then no tumor would be generated.
Second, grafts may be rejected by the recipients’ immune system.
The M13 iPSCs, originated from SD outbred rat, and feeder cells
of mouse origin remained in the prepared cell suspension, as
allografts and xenografts respectively, may induce rejection in
recipient SD rats. Third, grafts may be too small to be
distinguished in gross examination and fail to be sampled for
microscopic examination.
Although the underlying mechanisms for the tumorigenesis
observed in this study are not yet understood, there are several
possibilities. First, oncogene involvement and genome integration
might play a role, because the M13 rat iPSC line was induced
using integrating lentiviral vectors to deliver the four Yamanaka
factors, including the oncogene c-Myc. In such a scenario,
insertional mutagenesis and transgene reactivation can occur.
Besides, culture adaptation may have occurred because, although
these cells maintained a stable phenotype and karyotype in culture,
they may have undergone oncogenic transformation caused by
undetected genetic or epigenetic alterations. Furthermore, recent
studies have shown that iPSCs are not completely reprogrammed
to a ground state of pluripotency [18-20] and still retain some
epigenetic memory of their former fate, preferring to differentiate
Figure 2. Transplantation of undifferentiated rat iPSCs causes
tumorigenesis. A and B, Gross pathological evaluation revealed
visible tumors (white arrows) extending from the left ventricular wall
of the heart harvested 2 (A) or 6 (B) weeks after transplantation. The
ligature site is indicated (black arrow). C-I, Representative series of
hematoxylin-eosin-stained sections from harvested tumors. C, Heart
section from a myocardial infracted (MI) rat sacrificed 2 weeks after cell
transplantation showed an undifferentiated cell graft, magnified in D,
and osteogenic structures (mesoderm), magnified in E, in addition to
normal cardiac tissue (*). F, A clear-edged cartilaginous structure
(mesoderm) within the cardiac tissue from an intact rat sacrificed 4
weeks after cell transplantation. G, High magnification of the inset in F.
H, Neural rosettes (ectoderm) in a thoracic cavity tumor of an MI rat
sacrificed 4 weeks after cell transplantation. A boxed rosette is
magnified in I. Scale bars: 100 mm.
doi:10.1371/journal.pone.0019012.g002
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M13 iPSCs were induced from bone marrow cells, which may
explain the prevalence of chondro-osteogenic differentiation
observed in this study, in spite that M13 cells support the
differentiation into cell types of all three germ layers after
intramuscular injection into immunocompromised recipients [24].
Some most recent studies have reported that the reprogram-
ming process and subsequent culture of iPSCs in vitro can induce
genetic and epigenetic abnormalities in these cells, regardless of
the reprograming methods, integrating or non-integrating [25-29].
Potential risks exist in all stages of the induction of iPSCs and their
subsequent expansion. So iPSCs generated by any method should
Figure 3. Tumor incidence in rats after transplantation of undifferentiated rat iPSCs and differentiation of the tumors. A-C, Tumor
incidence in MI rats receiving different cell doses and/or subjected to various transplant durations. Cell dosage had no significant influence on tumor
incidence, regardless of transplant duration (A and B). Likewise, transplant duration had no significant influence on tumor incidence, regardless of
cell dose (A and C). D, There was no significant difference in tumor incidence between MI and intact rats. E, Intracardiac tumor incidence was
significantly higher than that of extracardiac tissues (P=0.001). F, Infarction had no significant influence on intracardiac/extracardiac tumor incidence.
G, The incidence of mesodermal differentiation was significantly higher than endodermal or ectodermal differentiation of tumors (P,0.001). H,
Intracardiac tumors had a lower incidence of ectodermal differentiation than extracardiac tumors (P=0.041), but no significant difference in the
incidence of mesodermal differentiation was found between intracardiac and extracardiac tumors. I, Infarction had no significant influence on tumor
differentiation.
doi:10.1371/journal.pone.0019012.g003
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their safety prior to clinical application.
In conclusion, our study demonstrates that, allogeneic iPSC
transplantation into the heart can cause in situ tumorigenesis in
immunocompetent recipients, and that the cells leaked from the
beating heart likely serve as a source of tumor spread. These
results imply that, for iPSC-based cardiac regeneration therapy,
the safety issue should be carefully addressed, and that the
elimination of undifferentiated cells from the grafts is necessary not
only in immunocompromised recipients but also in immunocom-
petent recipients. Therefore, further studies are warranted to
thoroughly examine the possible mechanisms of iPSC tumorige-
nicity, and to refine the techniques of directed differentiation and
purification of iPSC derived cardiomyocytes.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Experimental Animal Ethics
Committee of Nanjing Medical University (20100219), China.
All surgery was performed under pentobarbital anesthesia, and all
efforts were made to minimize suffering.
Cell Culture and Characterization
The M13 rat iPSC line, which was generated from adult SD rat
bone marrow cells by lentivirus-mediated transduction with Oct4,
Sox2, c-Myc and Klf4 [24], was kindly provided by Dr Lei Xiao
(Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences, Shanghai, China).
Rat iPSCs were maintained on irradiated mouse embryonic
fibroblast cells (MEFs, SiDanSai) in Knockout Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
ESC grade fetal bovine serum, 10% KnockOut serum replace-
ment, 0.1 mM non-essential amino acids, 1 mM L-glutamine, and
0.1 mM ß-mercaptoethanol (all from Invitrogen) [24]. Rat iPSCs
were dissociated into single cells with TrypLE (Invitrogen) and
split at a ratio of 1:5-1:15 every 2-3 days.
To form embryoid bodies, rat iPSCs were dissociated into single
cells and transferred to a Petri dish in differentiation medium
consisting of DMEM (Invitrogen) supplemented with 10% fetal
bovine serum (Thermo scientific) [24].
Alkaline phosphatase staining was performed 2 days after cell
passaging using an Alkaline Phosphatase Detection Kit (Millipore)
according to the manufacturer’s instructions.
Karyotyping was performed at the Xiangtan Center Hospital
using standard protocols for high-resolution G-banding. More
than 20 metaphase nuclei were examined.
Cell Preparation for Transplantation
M13 iPSCs at passage 22 to 24 were prepared for transplan-
tation. On transplantation day, cells in culture were enzymatically
dissociated into a single cell suspension containing undifferentiated
rat iPSCs and a considerable portion of MEFs. The mixed cell
suspension was plated into a culture flask and incubated for 15
minutes to allow most of the MEFs to attach, leaving mainly rat
iPSCs suspended. Undifferentiated rat iPSCs were then collected,
washed and re-suspended in Knockout DMEM. A MEF
suspension in Knockout DMEM was also prepared for transplan-
tation to provide a control for the possible confounding factor of
residual MEFs in the rat iPSC suspension. Harvested cells were
kept on ice for optimal viability prior to transplantation.
Rat Model of Myocardial Infarction and Cell
Transplantation
SD rats were housed under controlled conditions in a 12-hour
light/12-hour dark cycle at the Experimental Animal Center of
Nanjing Medical University, and were provided standard rodent
chow and water ad libitum.
A total of 151 female SD rats (6- to 10-wk-old, 200 to 250 g)
were subjected to the transplantation protocols summarized in
Table 1.
Specifically, rats were anaesthetized by intraperitoneal injection
of pentobarbital (50 mg/kg body weight, Roche). After endotra-
cheal intubation and initiation of ventilation (room air, rate 60
cycles/min, tidal volume 1 ml per 100 g of body weight), the heart
was exposed by left intercostal thoracotomy via a lateral incision
between the fourth and fifth ribs and the pericardium removed to
access the left anterior descending artery and its branch. Under
direct visualization, an 8-0 nylon atraumatic suture was passed
through the epicardial layer around the origin of the major
branch(es) and several minor branches of the left coronary artery
[30]. The ligatures were tied to occlude the coronary arteries,
while in sham-operated rats, the ligatures remained loose.
Myocardial ischemia was confirmed by ECG and color change
of the left ventricular wall.
Within 10 minutes after ligation, MI rats received intramyo-
cardial injections to the peri-infarct region at 3 different sites (30 ml
per site), using a 29-gauge needle attached to an insulin syringe;
while sham operated rats received no injection. The chest was
closed layer by layer with a 3-0 suture and rats were allowed to
recover under care.
Histological Study
After completion of the various survival periods, surviving rats
were euthanized with an overdose of pentobarbital (Roche).
Hearts were rapidly excised and autopsies were performed to
search for possible tumor formation in thoracic cavities, lungs,
livers, spleens and kidneys, and suspicious tissues were collected.
Explanted organs and tissues were fixed with 4% paraformade-
hyde for 24 hours (some of the heart specimens were frozen in
liquid nitrogen prior to fixation), then embedded in paraffin,
sectioned at 4 mm thickness and stained with haematoxylin-eosin.
Slides were evaluated by 2 independent pathologists who were
blinded to the study.
Statistics
Percentages were compared by chi-square test or Fisher’s exact
test. P,0.05 was predetermined as significant.
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